Login to Your Account



Hepatitis B Results Provide Boost To Dynavax's Stock

By Aaron Lorenzo


Thursday, November 30, 2006
Shares in Dynavax Technologies Corp. soared 32 percent Wednesday on positive Phase III data for its hepatitis B vaccine, Heplisav. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription